← Back to Search

Monoclonal Antibodies

TEV-53275 Dose B for Asthma

Phase 2
Waitlist Available
Research Sponsored by Teva Branded Pharmaceutical Products R&D, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 12 and 16

Summary

This trial tests a new injection called TEV-53275 for adults with a specific type of asthma that doesn't respond well to usual treatments. The medication works by lowering certain white blood cells to help improve breathing and reduce symptoms.

Eligible Conditions
  • Asthma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 12 and 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 12 and 16 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 12
Secondary study objectives
Change From Baseline in Asthma Control Questionnaire (ACQ-6) Score at Weeks 12 and 16
Change From Baseline in Asthma Control Test (ACT) Score at Weeks 12 and 16
Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 16
+20 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: TEV-53275 Dose BExperimental Treatment1 Intervention
Group II: TEV-53275 Dose AExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Teva Branded Pharmaceutical Products R&D, Inc.Lead Sponsor
256 Previous Clinical Trials
3,486,475 Total Patients Enrolled
64 Trials studying Asthma
2,616,846 Patients Enrolled for Asthma
Teva Medical Expert, MDStudy DirectorTeva Branded Pharmaceutical Products R&D, Inc.
97 Previous Clinical Trials
39,688 Total Patients Enrolled
23 Trials studying Asthma
13,275 Patients Enrolled for Asthma
~21 spots leftby Dec 2025